Revolution's lifesaving pancreatic cancer drug wins speedy FDA approval

The U.S. FDA has approved Revolution Medicines' pancreatic cancer drug Rasonque, which doubles survival rates for metastatic patients and is available with co-pay assistance. The drug's rapid approval under the FDA's expedited review process reflects significant unmet medical need and creates a new treatment option for a typically lethal cancer.

This Wire brief sits within Fusion42's coverage of Biotech, and 48 sources have reported it between 26 Aug 2026 and 16 Oct 2026.